Deciphering the immunogenicity of cell death using systematic genetic tools
Project Number1DP2AI184830-01
Contact PI/Project LeaderKAMBER, ROARKE ALEXANDER
Awardee OrganizationUNIVERSITY OF CALIFORNIA, SAN FRANCISCO
Description
Abstract Text
Project Summary
Professional phagocytes, including macrophages and dendritic cells, engulf approximately 200 billion dead cells
per day in humans. The vast majority of dead cells are consumed “silently,” in that the phagocyte does not trigger
an adaptive immune response targeting the material in the engulfed cell, thereby maintaining tolerance of self.
Phagocytes play a critical role in maintaining self-tolerance, and their accurate decision-making during
phagocytosis is essential for avoiding catastrophic immune rejection of self antigens. On the other hand,
immunogenic cell death (ICD), in which an engulfed cell is interpreted as having died following infection with a
pathogen, is critical for launching an effective immune response against viral pathogens and tumors. The
immunogenicity of pathogen-induced cell death is known to depend on the detection of pathogen-associated
molecular patterns (PAMPs) by pattern recognition receptors (PRR) in phagocytes. By contrast, the mechanisms
governing the regulation of ICD in sterile contexts (such as autoimmunity and cancer) are significantly less well
understood. Our lack of knowledge of the molecular signals that govern ICD directly impedes our ability to
develop rational therapeutic strategies to either trigger or suppress ICD. We argue that the absence of systematic
genetic tools for understanding this complex, inter-cellular process has critically hindered the progression of the
ICD field. We propose a systematic approach for investigating the mechanisms governing ICD, building on our
recent development of a suite of platforms for high-throughput interrogation of the genetics of myeloid cell biology.
We will focus our efforts on three key “blind spots” in our knowledge of the three sequential stages of ICD: 1) the
mechanism of calreticulin-independent cellular uptake, 2) the mechanism of DAMP/adjuvant release by dead cells,
and 3) the mechanisms governing PRR-driven antigen presentation in APCs. The project is designed to have high
impact by providing the first systematic investigations of this core immunological process and by potentiating
therapeutic targeting of these pathways in autoimmunity, cancer, and infectious diseases.
Public Health Relevance Statement
Project Narrative
The core function of immunity is to distinguish self from non-self, yet in the process of sterile immunogenic cell
death, our immune system recognizes our own dead cells as foreign. This process can thus lead to autoimmunity,
though it can also be useful in cancer treatment if induced in the right time and place. This proposal seeks to
apply breakthrough functional genomic technologies to interrogate the molecular basis of immunogenic cell
death and potentiate new treatments in autoimmunity, cancer, and other diseases of the immune system.
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
094878337
UEI
KMH5K9V7S518
Project Start Date
15-August-2024
Project End Date
31-July-2029
Budget Start Date
15-August-2024
Budget End Date
31-July-2025
Project Funding Information for 2024
Total Funding
$492,000
Direct Costs
$300,000
Indirect Costs
$192,000
Year
Funding IC
FY Total Cost by IC
2024
National Institute of Allergy and Infectious Diseases
$492,000
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 1DP2AI184830-01
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1DP2AI184830-01
Patents
No Patents information available for 1DP2AI184830-01
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1DP2AI184830-01
Clinical Studies
No Clinical Studies information available for 1DP2AI184830-01
News and More
Related News Releases
No news release information available for 1DP2AI184830-01
History
No Historical information available for 1DP2AI184830-01
Similar Projects
No Similar Projects information available for 1DP2AI184830-01